Renowned neuroscientist Dr. Kim Q. Do unveils novel approach to schizophrenia treatment

Lausanne, Switzerland - The "Innovators & Ideas: Research Leader" section of Brain Medicine (ISSN: 2997-2639), published by Genomic Press, New York, features an illuminating Genomic Press Interview with Professor Kim Q. Do, a trailblazer in schizophrenia research at the University of Lausanne. The interview delves into Do's pioneering work on oxidative stress in psychiatric disorders and her innovative approach to treating schizophrenia using mitochondria-targeted antioxidants.

Professor Do, who served as the head of the Unit for Research in Schizophrenia at the Center for Psychiatric Neuroscience, shares her journey from a young student in war-torn Vietnam to a leading figure in neuroscience. Her work focuses on understanding the role of oxidative stress in schizophrenia and developing novel treatments that target mitochondrial function.

"Our research aims to address the complex challenges linked to schizophrenia, from genetics and pathophysiology to clinical presentation and disease progression," Professor Do explains. "We're particularly excited about our current clinical trial centered on an antioxidant specifically targeted at mitochondria."

The Genomic Press Interview highlights Do's current research focus on parvalbumin interneurons (PVI), which are crucial for cognitive, affective, and social activities and are impaired in patients with schizophrenia. Her team's work suggests that mitochondria-targeted antioxidants could significantly alleviate symptoms and improve cognitive functions in schizophrenia patients – areas where current antipsychotics often fall short.

Do's work represents a significant advancement in the field of psychiatric research. By combining basic neuroscience with clinical psychiatry, she is bridging the gap between laboratory findings and patient care. Her studies on the role of glutathione deficiency in schizophrenia have been particularly groundbreaking, offering new perspectives on the molecular mechanisms underlying the disorder.

The interview also touches on Do's personal journey, including her early experiences in Vietnam and her path to becoming a leader in neuroscience. This unique background has shaped her approach to research, emphasizing the importance of diversity and interdisciplinary collaboration in scientific endeavors.

"Professor Do's work exemplifies the innovative research being conducted at the intersection of neuroscience and psychiatry," says Dr. Julio Licinio, Editor-in-Chief of Brain Medicine. "Her insights into the role of oxidative stress and mitochondrial dysfunction in schizophrenia are not only advancing our understanding of the condition but also paving the way for more effective, targeted interventions."

The Genomic Press Interview with Professor Kim Q. Do offers a fascinating glimpse into the life and work of a scientist at the forefront of schizophrenia research. It underscores the potential of antioxidant therapies to revolutionize our approach to treating this complex disorder, potentially improving the lives of millions affected by schizophrenia worldwide.

Do emphasizes the importance of a multidisciplinary approach to psychiatric research, breaking down barriers between basic scientists and clinicians. Her commitment to fostering the next generation of psychiatrists with expertise in both clinical practice and neuroscience exemplifies the best of academic medicine.

The full Genomic Press Interview "Kim Q. Do: Antioxidants specifically targeted at mitochondria: A novel therapeutic approach to schizophrenia" was published on 28 March 2024, and is available online in the Innovators & Ideas: Research Leader section of Brain Medicine: https://bm.genomicpress.com/aop/.

About Brain Medicine: Brain Medicine (ISSN: 2997-2639) is a peer-reviewed journal published by Genomic Press, New York. Brain Medicine is a new home for the cross-disciplinary pathway from innovation in fundamental neuroscience to translational initiatives in brain medicine. The journal’s scope includes the underlying science, causes, outcomes, treatments, and societal impact of brain disorders, across all clinical disciplines and their interface.